Search
forLearn
5 / 801 resultslearn sanguisorba officinalis
learn Carotene
learn vitamin k
learn iris florentina
Research
5 / 1000+ results
research Increasing tinea capitis prevalence in Stockholm reflects immigration
The rise in tinea capitis cases in Stockholm is linked to increased African immigration.
research BRAIN HEALTH SERVICES – A NEW APPROACH TO PREVENTING ALZHEIMER’S DISEASE
Structured prevention strategies and Brain Health Clinics can help prevent Alzheimer's.
research Development of a mouse model for Hutchinson-Gilford progeria syndrome reveal defects in adult stem cell maintenance
The mouse model showed defects in adult stem cell maintenance related to Hutchinson-Gilford progeria syndrome.
research Studies on basal cell carcinoma with emphasis on the role of the human homologue of the Drosophila patched gene
PTCH gene mutations contribute to basal cell carcinoma development.
research Telogen effluvium: a sequela of COVID‐19
COVID-19 may cause a temporary hair loss condition called telogen effluvium in some patients after recovery.
Community Join
5 / 1000+ resultscommunity C’est terrible - at my wits end
A 29-year-old woman is experiencing gradual hair thinning since age 15, suspects Androgenic Alopecia, and has tried 5% minoxidil with little success. She has purchased various hair loss treatments including minoxidil, dutasteride, finasteride, and spironolactone, but is cautious about starting them due to potential interactions with her ADHD medication.
community September 2021 update from Dr. Kang-Yell Choi [Korean "cure"]
Dr. Kang-Yell Choi's company, CK Regeon, is developing a drug called KY19382 for hair regeneration, which involves creating fine wounds to activate stem cells. The drug is in the formulation development stage, targeting markets like the US and Korea.
community Kintor Pharma Announced Successful Dosing of the First Patient for Acne Vulgaris Phase II Clinical Trial of KX-826
Kintor Pharma successfully dosed the first patient in a Phase II trial for KX-826 for acne vulgaris. Users are more interested in results for male pattern baldness (MPB).
community Kintor's KX-826 Phase 2 data release is officially pushed back to September due to COVID:
Hair loss discussion includes treatments Min, Fin, and RU. Kintor's KX-826 Phase 2 data release delayed to September due to COVID.
community Kintor Pharma Announces Successful Completion of Phase II Clinical Trial of KX-826 for Treatment of Androgenetic Alopecia in the US
Kintor Pharma completed a successful Phase II clinical trial for KX-826, a treatment for androgenetic alopecia. KX-826 is similar to finasteride with minor side effects and is more backed than Cosmerna.